Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system

Haejin Oh, Jinsil Seong, Wonwoo Kim, Sooyeon Park, Woong Sub Koom, Namhoon Cho, Mihee Song

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

This study was to investigate whether RHEGF protects radiation induced intestine injury without compromising antitumor effect of radiation in murine system. A radiation induced intestinal injury model was established in mice by whole body irradiation. Using this model, 4 groups were set; control, RHEGF (100 μg/kg intraperitoneally), radiation (10 GY), and a combination (RHEGF and radiation). The level of apoptosis and proliferation were analyzed by TUNEL assay and proliferation cell nuclear antigen (PCNA) immunohistochemical staining, respectively, as well as observation of survival and body weight change. A tumor growth delay assay was performed using murine syngeneic tumors; one radioresistant tumor, HCA-I and one radiosensitive tumor, MCA-K. In the radiation induced intestinal injury model, the 10 GY group had significantly more weight loss with less number of crypt cells and higher apoptosis than the 8 GY group. Using 10 GY model, radioprotective effect of RHEGF was tested. Addition of RHEGF improved not only the body weight loss but also survival following radiation. It also induced suppression of apoptosis as well as increase of PCNA expression and recovery of villi. RHEGF did not enhance the tumor growth after radiation exposure in the tested tumors. These findings suggest that combination of exogenous RHEGF and radiation can be a new anticancer strategy by protecting radiation-induced intestinal injury without alleviating antitumor effect of radiation.

Original languageEnglish
Pages (from-to)535-541
Number of pages7
JournalJournal of Radiation Research
Volume51
Issue number5
DOIs
Publication statusPublished - 2010 Nov 2

Fingerprint

intestines
Epidermal Growth Factor
Intestines
Radiation
Wounds and Injuries
radiation
tumors
apoptosis
Neoplasms
Nuclear Antigens
Radiation Effects
Apoptosis
body weight
Weight Loss
antigens
Cell Proliferation
Body Weight Changes
cells
Survival
Whole-Body Irradiation

All Science Journal Classification (ASJC) codes

  • Radiation
  • Radiology Nuclear Medicine and imaging
  • Health, Toxicology and Mutagenesis

Cite this

Oh, Haejin ; Seong, Jinsil ; Kim, Wonwoo ; Park, Sooyeon ; Koom, Woong Sub ; Cho, Namhoon ; Song, Mihee. / Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system. In: Journal of Radiation Research. 2010 ; Vol. 51, No. 5. pp. 535-541.
@article{6fd71ce52ccd45538db59c3128bf19a0,
title = "Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system",
abstract = "This study was to investigate whether RHEGF protects radiation induced intestine injury without compromising antitumor effect of radiation in murine system. A radiation induced intestinal injury model was established in mice by whole body irradiation. Using this model, 4 groups were set; control, RHEGF (100 μg/kg intraperitoneally), radiation (10 GY), and a combination (RHEGF and radiation). The level of apoptosis and proliferation were analyzed by TUNEL assay and proliferation cell nuclear antigen (PCNA) immunohistochemical staining, respectively, as well as observation of survival and body weight change. A tumor growth delay assay was performed using murine syngeneic tumors; one radioresistant tumor, HCA-I and one radiosensitive tumor, MCA-K. In the radiation induced intestinal injury model, the 10 GY group had significantly more weight loss with less number of crypt cells and higher apoptosis than the 8 GY group. Using 10 GY model, radioprotective effect of RHEGF was tested. Addition of RHEGF improved not only the body weight loss but also survival following radiation. It also induced suppression of apoptosis as well as increase of PCNA expression and recovery of villi. RHEGF did not enhance the tumor growth after radiation exposure in the tested tumors. These findings suggest that combination of exogenous RHEGF and radiation can be a new anticancer strategy by protecting radiation-induced intestinal injury without alleviating antitumor effect of radiation.",
author = "Haejin Oh and Jinsil Seong and Wonwoo Kim and Sooyeon Park and Koom, {Woong Sub} and Namhoon Cho and Mihee Song",
year = "2010",
month = "11",
day = "2",
doi = "10.1269/jrr.09145",
language = "English",
volume = "51",
pages = "535--541",
journal = "Journal of Radiation Research",
issn = "0449-3060",
publisher = "Japan Radiation Research Society",
number = "5",

}

Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system. / Oh, Haejin; Seong, Jinsil; Kim, Wonwoo; Park, Sooyeon; Koom, Woong Sub; Cho, Namhoon; Song, Mihee.

In: Journal of Radiation Research, Vol. 51, No. 5, 02.11.2010, p. 535-541.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Recombinant human epidermal growth factor (rhEGF) protects radiation-induced intestine injury in murine system

AU - Oh, Haejin

AU - Seong, Jinsil

AU - Kim, Wonwoo

AU - Park, Sooyeon

AU - Koom, Woong Sub

AU - Cho, Namhoon

AU - Song, Mihee

PY - 2010/11/2

Y1 - 2010/11/2

N2 - This study was to investigate whether RHEGF protects radiation induced intestine injury without compromising antitumor effect of radiation in murine system. A radiation induced intestinal injury model was established in mice by whole body irradiation. Using this model, 4 groups were set; control, RHEGF (100 μg/kg intraperitoneally), radiation (10 GY), and a combination (RHEGF and radiation). The level of apoptosis and proliferation were analyzed by TUNEL assay and proliferation cell nuclear antigen (PCNA) immunohistochemical staining, respectively, as well as observation of survival and body weight change. A tumor growth delay assay was performed using murine syngeneic tumors; one radioresistant tumor, HCA-I and one radiosensitive tumor, MCA-K. In the radiation induced intestinal injury model, the 10 GY group had significantly more weight loss with less number of crypt cells and higher apoptosis than the 8 GY group. Using 10 GY model, radioprotective effect of RHEGF was tested. Addition of RHEGF improved not only the body weight loss but also survival following radiation. It also induced suppression of apoptosis as well as increase of PCNA expression and recovery of villi. RHEGF did not enhance the tumor growth after radiation exposure in the tested tumors. These findings suggest that combination of exogenous RHEGF and radiation can be a new anticancer strategy by protecting radiation-induced intestinal injury without alleviating antitumor effect of radiation.

AB - This study was to investigate whether RHEGF protects radiation induced intestine injury without compromising antitumor effect of radiation in murine system. A radiation induced intestinal injury model was established in mice by whole body irradiation. Using this model, 4 groups were set; control, RHEGF (100 μg/kg intraperitoneally), radiation (10 GY), and a combination (RHEGF and radiation). The level of apoptosis and proliferation were analyzed by TUNEL assay and proliferation cell nuclear antigen (PCNA) immunohistochemical staining, respectively, as well as observation of survival and body weight change. A tumor growth delay assay was performed using murine syngeneic tumors; one radioresistant tumor, HCA-I and one radiosensitive tumor, MCA-K. In the radiation induced intestinal injury model, the 10 GY group had significantly more weight loss with less number of crypt cells and higher apoptosis than the 8 GY group. Using 10 GY model, radioprotective effect of RHEGF was tested. Addition of RHEGF improved not only the body weight loss but also survival following radiation. It also induced suppression of apoptosis as well as increase of PCNA expression and recovery of villi. RHEGF did not enhance the tumor growth after radiation exposure in the tested tumors. These findings suggest that combination of exogenous RHEGF and radiation can be a new anticancer strategy by protecting radiation-induced intestinal injury without alleviating antitumor effect of radiation.

UR - http://www.scopus.com/inward/record.url?scp=77958566383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958566383&partnerID=8YFLogxK

U2 - 10.1269/jrr.09145

DO - 10.1269/jrr.09145

M3 - Article

VL - 51

SP - 535

EP - 541

JO - Journal of Radiation Research

JF - Journal of Radiation Research

SN - 0449-3060

IS - 5

ER -